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their relative importance weights (%) were: robustness of clinical evidence (31%);
robustness of CE estimates (25%); availability of alternative treatments (8%); incre-
mental efficacy (8%); relative safety (7%); ease of adoption (7%); incremental impact
on QOL (5%); budget impact (4%); unmet need (3%); size of population (1%). The
attribute levels and relative value for a positive reimbursement recommendation
(0-1) for the most important attribute, robustness of clinical evidence, were: ‘end-
points and/or comparators not relevant to payers’ (0); ‘weak intermediate clinical
endpoints, indirect comparisons needed’ (0.25); ‘all clinical endpoints and compar-
ators relevant for NHS’ (1). The estimates of the probability of a favorable reim-
bursement recommendation for the hypothetical products included in the post-
workshop questionnaire using the logistic regression model had 71% positive
predictive value and 91% negative predictive value when compared to participant
decisions for these hypothetical products provided in responses to the post-work-
shop questionnaire. CONCLUSIONS: An MCDA process can provide both a qualita-
tive understanding and quantitative estimates of the relative importance, attribute
levels, and value scales of different product attributes that influence a positive
reimbursement decision in the UK.
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OBJECTIVES: The meaning of ‘value’ and the criteria for judging it are increasingly
being debated in countries with established reimbursement processes using
Health Technology Assessment (HTA). The objective of this study is to determine
the criteria used in decision-making to determine value in OECD countries’ deci-
sion-making processes using health economic analysis (HEA).METHODS:A review
of reimbursement agencies’ websites, relevant literature and contact with individ-
ual agencies identified the criteria used to determine value for medicines in pro-
cesses using HEA. Countries are categorised by how HEA is used in decision-mak-
ing processes, nature of the cost-effectiveness threshold range (explicit, implicit,
no threshold), threshold range where identified and the use of such evidence
alongside other decision-making criteria (burden of disease, severity, innovation
and others). Details of the judgments reported with respect to the criteria in doc-
uments justifying the decision are examined. RESULTS: Twenty-four OECD coun-
tries use formal HTA of which 17 require HEA in submissions for certain medicines.
Cost-effectiveness thresholds are identified in nine countries, explicitly stated in
three. Implicit threshold ranges are identified in four (based on past decisions),
whilst in two implicit willingness-to-pay thresholds are used for decision-making.
Use of HEA is always accompanied by other criteria (severity, need, burden of
disease, end of life, innovation, amongst others). Some countries use cost-effec-
tiveness thresholds central to their decision-making, some report them equally
amongst other criteria, whilst in others it is unclear how such criteria is judged.
Details relating to the judgement of criteria used in appraisals are sparse.
CONCLUSIONS: Multiple criteria are common in countries using HEA, although
some are country specific. Reporting of these criteria and their respective use and
interpretation alongside the cost-effectiveness threshold range suggests variation
in the meaning of value. Multi-criteria decision analysis could provide clarity in the
justification of the reimbursement decision and the meaning of value.
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OBJECTIVES: During 2011-2012 significant price cuts were implemented in various
markets in the European Union. These price cuts have introduced new pricing
dynamics affecting reference pricing and intra-EU parallel export of expensive
drugs. METHODS: To understand new pricing dynamics in the big five EU (UK,
France, Germany, Italy and Spain) we analyzed the trend in pricing for branded and
biosimilar GM-CSF products. Prices were analyzed for percentage discount com-
pared to branded GM-CSF product and relative price levels in five selected markets.
Recent reimbursement policy changes, and price cuts were also analyzed.
RESULTS: The 2012 prices for GM-CSF products show significant variation across
UK, France, Germany, Italy and Spain. The prices for GM-CSF products were dra-
matically lower in Spain and UK compared to France, Germany and Italy. For ex-
ample, for branded GM-CSF product prices in Spain were 80% lower than prices in
the UK. Similarly, the prices for biosimilar GM-CSF products were 72% lower in
Spain than in the UK. The percentage price discount for biosimilar products versus
branded product also shows large variation in big five EU markets. For example,
Spain and UK prices were almost at parity while the prices in France, Germany and
Italy showed 12%, 31% and 26% discount, respectively.CONCLUSIONS: Recent pric-
ing reforms have significantly changed the pricing dynamic across big five EU
markets. Case study of GM-CSF products illustrates wide variation in pricing for
branded and biosimilar products.
PHP121
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OBJECTIVES: In France, reimbursement of drugs is based on the therapeutic value
of drugs (SMR level for each indication) as assessed by HAS, going from “insuffi-
cient” (no reimbursement at all) to “weak” (15% reimbursement), “moderate” (30%)
and “important” (65%). HAS and manufacturer have the right to ask for re-assess-
ment anytime after the initial reimbursement listing; in all cases, a relisting pro-
cess is compulsory every 5 years. We analyzed HAS’s reassessment and relisting
activity over the year 2011, based on the hypothesis that the Mediator safety “af-
fair” would have impacted the process. METHODS: We considered all complete
procedures for relisting, re-assessments and class reviews and focused on drugs for
which a HAS advice was published between Jan and Dec 2011. We compared pre-
vious and new SMR levels for each indication. RESULTS: Twenty-six drugs have
gone the relisting process, corresponding to 33 different indications, out of which
31 cases were analyzable: HAS modified 14 SMRs while 17 SMRs remained un-
changed. Almost 50% (6/13) of SMR initially rated as “important” were changed to
“insufficient” (4) or “moderate” (2). All initially insufficient SMR (8) were confirmed.
19 drugs have gone through re-assessment process, corresponding to 24 SMRs/
indication, out of each only 21 were analyzable: 10 SMRs have been modified (only
2 increased and the rest lowered) and 11 unchanged. In 8 of these cases, the man-
ufacturer had asked for the re-assessment. 6 full therapeutic classes have been
reviewed in 2011, including Alzheimer’s and antipschychotics, resulting in a har-
monization and a decrease of the SMR levels. CONCLUSIONS: Manufacturers
should now ensure that reassessment and relisting dossiers in France incorporate
as much of relevant clinical, safety and real-life information as possible in order to
maintain the reimbursement level.
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OBJECTIVES: Every day health care decison makers on the national, regional and
local level face the challenge of making complex funding decisions. The complexity
in drug funding decisions comes from balancing quantitative criteria such as clin-
ical evidence and qualitative criteria such as personal experience of decison mak-
ers. This systematic literature review reflects the research status on applied criteria
in drug funding decisions. METHODS: Relevant literature has been identified by
using a systematic database search process as described by Tranfield, Denyer &
Smart (2003) via EBSCO and Science Direct. Topic relevant search terms were ap-
plied which resulted in 412 papers. Detailed screening of the paper abstracts with
application of inclusion criteria reduced the number of relevant papers down to 20.
Following this, information from those 20 papers has been analysed and compared
to practitioner experience. RESULTS: The most discussed criteria with influence on
drug funding decisions were the importance and use of economic evaluations and
the importance of political and social factors for the decision process. Both topics
were discussed in six studies (30% each). More than half of the studies (14 out of 20)
showed evidence that drug funding decisions are decided not only by quantitative
criteria, but also decided by qualitative criteria. Another finding was a geographical
research prioritization. The most discussed country in the relevant studies was the
UK (23%) followed by Canada (15%), the Netherlands (13%), Australia, France and
the USA (each 10%). CONCLUSIONS: Relevant research literature shows the exis-
tence of quantitative criteria influencing drug funding decision-making but also
the use of qualitative criteria seems to be proved. Although this is seldom docu-
mented publicly, qualitative criteria are shown to have an impact on drug funding
decisions. Further research work is necessary to extend knowledge about the im-
pact of qualitative criteria in drug funding decision-making.
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OBJECTIVES:Health-related quality of life (HRQoL) might be one important patient
reported endpoint (PRO) in determining the additional benefit of pharmaceuticals
recently evaluated according to the newly established German law for reforming
the market for pharmaceuticals (AMNOG). A comparative analysis is performed to
gain insight how HRQoL was implemented in the benefit dossier by the pharma-
ceutical manufacturer on the one hand and how it was assessed in the benefit
assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) on the
other hand. METHODS: We reviewed 23 published benefit dossiers and the corre-
sponding benefit assessments, which the IQWiG performed since the implemen-
tation of the AMNOG in 2011. Corresponding statements concerning HRQoL in
benefit dossiers and benefit assessment were faced narrative. RESULTS: Eighteen
benefit dossiers reported HRQoL and a number of validated instruments were used,
which were generally accepted by the IQWiG if not for major mistakes in the benefit
dossiers (for example the use of another appropriate comparator). Overall, the
pharmaceutical manufacturers have difficulties to clearly prove an additional ben-
efit due to HRQoL because the used studies do not contain data on this endpoint or
the results are statistical non-significant. The IQWiG draws a similar conclusion as
the pharmaceutical manufacturers and attests none of the benefit dossiers an
additional benefit due to HRQoL. A common methodological problem reported in
the benefit assessments is for example a low response rate so that the data has high
bias potential. CONCLUSIONS: None of the published benefit assessments state an
additional benefit in HRQoL although this is an important PRO and the pharmaceu-
tical manufacturers presented a range of accepted validated instruments to assess
it. Dealing with data uncertainties concerning the HRQoL has to be accomplished in
the future of the benefit assessment.
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OBJECTIVES: Submitting an HTA dossier a cardinal step in gaining market access
for new drugs. While funding decisions lay on an array of criteria a well designed
global value dossier (GVD) will facilitate development of national dossiers. In order
to gain a better understanding of the optimal structure of a GVD we reviewed
differences in requirements and recent changes in countries like Germany and
Spain. METHODS: Country-specific guidelines for HTA submissions and dossiers
submitted in the last 3 years have been scrutinized to identify the key differences
across European agencies (AWMSG, CVZ, DGFPS, G-BA, HAS/CEPS, NCPE, NICE,
SMC, TLV). Criteria reviewed included the guidelines strictness, and the need of
comparative effectiveness, health economic and budget impact evidence.
RESULTS: The majority of agencies reviewed (89%) have a well defined template
but the outline differs markedly between them. Differences relate to the requested
contents (clinical and budgetary outcomes only [33%] vs. a more cost-effectiveness
framework [67%]), and to the perspective from which the evidence is reviewed
(societal [17%] versus national health system or statuary health insurance perspec-
tive [83%]). Additional differences are the preferred type of economic model (cost
utility versus cost per clinical benefit) and budget impact (incremental budget im-
pact versus net costs) and weight given to indirect treatment comparisons when
head-to-head studies are lacking. CONCLUSIONS:Our review illustrates the lack of
standardization of the requirements across European HTAs. This renders the de-
velopment of a GVD easily adaptable to country-specific submissions, a difficult
task. Our review suggests that the GVD should be orchestrated around the needs
for NICE and implemented with the particularities of the different HTAs.
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OBJECTIVES:To provide early assessment of the process for reimbursement of new
drugs by the German Federal Joint Commission (GBA), which assesses “additional
clinical benefit” (ACB) for the new drug compared to an appropriate comparator.
METHODS: A database was created including the decisions by product and indica-
tion. A qualitative and descriptive statistical analysis was performed to examine
the relationship of ACB decisions to comparators, population size and complete-
ness of the submission. RESULTS: The database included data for 20 final resolu-
tions assessing ACB. Different descriptors of ACB have been used by the GBA in the
published resolutions including: “no additional benefit”; “small clinical benefit”;
“indication of additional clinical benefit, not quantifiable”; or “considerable clinical
benefit”. In 8 (40%) of the final resolutions, ACB was not proven, in 5 (25%) submis-
sions ACB was proven for the indicated population, and in 7 (35%) ACB was proven
only in a subset of the indicated population. For 3 of the 5 submissions where ACB
was proven for the indicated population, the resolution was based on the fact that
this was an orphan drug. Lack of data on an appropriate comparator was given as
the reason for the not proven decision for 4 submissions. The dossier was consid-
ered incomplete for 2 submissions. For three drugs, one for hypertension, one for
hypercholesterolemia and one for postoperative ocular inflammation following
cataract extraction, no dossiers were submitted and the products were allocated to
the appropriate reference price group. CONCLUSIONS: With the exception of res-
olutions for orphan drugs, all but two of the early ACB decisions have found proof
of benefit in only a subgroup of the indicated population. Lack of data on an appro-
priate comparator and target patient population was a common reason for a neg-
ative resolution.
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OBJECTIVES: Health economics and outcomes research (HE&OR) have become in-
creasingly important for Dutch policy makers to decide on the content of the stat-
utory insurance package. Pharmaceutical companies have been well developed in
conducting outcomes research and presenting health economics data in order to
access the insurance package, and reimbursement for their products. However,
HE&OR data are not the only objectives for successful reimbursement strategies.
The objective of this study was to analyse reimbursement trajectories in order to
unravel factors for successful market access. METHODS: A qualitative, retrospec-
tive study have been performed from 2008-2011. Period of study: 1999 -2010. In this
study market access trajectories of the three main TNF -blockers, and several
smaller trajectories of pharmaceutical and medical devices companies have been
analysed. Governmental and company documents and value dossiers were studied
and interviews (n19) were held with decision makers of the Ministry, the Health
Insurance Board, physicians, patient organizations, and responsible persons from
the companies. Because the financial reimbursement scheme in the Netherlands
has been changed by January 1st2012, the results are reanalysed and latest results
are added. RESULTS: Within the Dutch health care system, based on a neo-corpo-
ratist structure, many parties are involved in decision making processes. Pharma-
ceutical companies, scientific associations of physicians, and well-developed pa-
tient organizations are being invited to consultations with policy makers and the
Ministry. Our analysis shows that in depth knowledge of Dutch financing scheme
needs to be accompanied with mutual trust and converging goals of the several
parties. Those goals can easiest be converged on patients’ level. CONCLUSIONS:
Although Dutch policy makers are emphasising HE&OR for accessing the insurance
package, our study shows that important arguments for successful market access
are institutional trust and converging goals of the several parties and, from January
1, 2012, in-depth knowledge of the Dutch dedicated DRG-system.
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OBJECTIVES: Orphan drugs are subject to regulatory and reimbursement regula-
tions that differ with respect to application process and necessary documentation.
An orphan drug status granted by the European Commission gives marketing ex-
clusivity in the EU for 10 years after approval. Reimbursement hurdles are also
supposedly lower for orphan drugs in Europe than usually. METHODS: Definition
and assessment process of orphan drugs for reimbursement were reviewed and
analyzed. Differences to other drugs are outlined and reimbursement decisions
presented. RESULTS: The German law on health care reform (AMNOG) imple-
mented in 2011 requires that with market access newly approved products dem-
onstrate their innovation through a reimbursement dossier to avoid reference
group pricing. For orphan drugs, manufacturers must also submit a dossier but the
additional medical benefit is regarded as having been proofed by the market au-
thorization itself. Thus proof of additional benefit does not need to be presented
but information on relevant patient groups and on the extent of this additional
benefit. However, if annual sales of an orphan drug within the statutory health
insurance exceed 50 million EUR, a full assessment is made. For pirfenidone, the
first orphan drug assessed under the new law, IQWiG (Institute for Quality and
Efficiency in Health Care) declined an additional therapeutic benefit but the G-BA
(Joint Federal Committee) did not follow this conclusion in accordance to the law.
In Italy pirfenidone was grouped into the lowest reimbursement class. Unlike Ger-
many, Italy has special funds set aside for orphan drugs, France has an early access
program, and many countries are struggling with how to create a reimbursement
process that reflects the different regulatory provisions for orphans.
CONCLUSIONS: Although orphan drugs are often regarded as unquestioned reim-
burseable, differences in respective processes and assessments exists. Manufac-
turers are requested to build Market Access arguments carefully and expect chal-
lenges in orphan drug indications as well.
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OBJECTIVES: In 2011, Germany’s new health care reform (AMNOG) came into effect
requiring that with market access newly approved products demonstrate their
innovation to avoid reference group pricing. The manufacturer has to submit a
dossier proving additional benefit versus the appropriate comparator recom-
mended by the G-BA (Joint Federal Committee). On request of the G-BA, IQWiG
(Institute for Quality and Efficiency in Health Care) reviews the dossier and per-
forms the benefit assessment. Manufacturers, associations and experts can submit
comments and attend a hearing; thereafter the G-BA publishes its final resolution.
METHODS: Benefit assessments and G-BA decisions to date were reviewed and
analyzed case by case. Differences between IQWiG and G-BA evaluations are out-
lined and consequences depicted. RESULTS: Up to now 32 dossiers have been
submitted, 19 completed the whole process and further 8 will be finally assessed
shortly. About half of the products additional therapeutic benefit was granted al-
lowing price negotiations with the statutory health insurance. Not in all cases did
the G-BA follow IQWiG’s conclusions as for Eribulin and Pirfenidone (an Orphan
drug). The selection of the appropriate comparator treatment was the most con-
troversial issue between G-BA and pharmaceutical companies, followed by ques-
tions about evidence for and interpretation of benefit. Thus for Linagliptin no ad-
ditional benefit against the appropriate comparator is proven according to the G-BA
and the manufacturer challenges the process. Other critical methodology issues
included the definition of patient-relevant endpoints, use of surrogate endpoints,
determination of target patient populations and use of subpopulations.
CONCLUSIONS: Although in its second year, AMNOG is still a learning process for
all parties involved. Before initiating a dossier it is crucial to investigate possible
pitfalls around dossier development. New questions will emerge when it comes to
the assessment of drugs already on the market as it is now planned for DPP-4
inhibitors.
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OBJECTIVES: Exploring the use of population-level epidemiological data (i) within
the reimbursement decision making process, (ii) identifying recommendations and
requirements on that data, and (iii) investigating the role of that data for reim-
bursement decisions as stated in pharmacoeconomic guidelines. METHODS: We
piloted a comparative review of all national pharmacoeconomic guidelines pub-
lished in English (N26 out of 33) available through the ISPOR Website
http://www.ispor.org/PEguidelines/index.asp. RESULTS: The use of population-
level epidemiological data was addressed by 20 guidelines.16 mentioned the use
for economic evaluations, 4 (additionally) for budget impact analyses, and 4 (also)
for broader technology assessments. 14 guidelines provided explicit recommenda-
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